Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PGD | P52209 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | STAT6 | P42226 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1595065 | 1.00 | SUCNR1 (0.45) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL27159744 | 1.00 | SUCNR1 (0.45) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL10473227 | 1.00 | SUCNR1 (0.45) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL1727954 | 1.00 | SUCNR1 (0.45) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL18219198 | 0.90 | SUCNR1 (0.38) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL18219558 | 0.90 | SUCNR1 (0.38) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL13997318 | 0.87 | SUCNR1 (0.39) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL26678742 | 0.87 | SUCNR1 (0.39) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL14007051 | 0.87 | SUCNR1 (0.39) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 | |
| SCHEMBL5048000 | 0.87 | SUCNR1 (0.39) | SUCNR1MAPK1NPSR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882703-B1 | CYCLIC AMIC ACID DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2002-08-14 | — | — | EP | claimed |
| US-9152005-B2 | Particle dispersion for display, display medium, and display device | FUJI XEROX CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| CN-103728805-A | Particle dispersion for display, display medium, and display device | FUJI XEROX CO LTD | 2014-04-16 | — | — | CN | disclosed |
| CN-101528749-B | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | IND RES LTD | 2013-07-31 | — | — | CN | disclosed |
| US-7919653-B2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2011-04-05 | — | — | US | disclosed |
| EP-2157429-A2 | Method of inhibiting nonspecific interaction between molecules on solid phase support | Reverse Proteomics Research Institute Co., Ltd (JP) | 2010-02-24 | — | — | EP | disclosed |
| CN-101528749-A | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | IND RES LTD (NZ) | 2009-09-09 | — | — | CN | disclosed |
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1553412-A1 | METHOD OF INHIBITING NONSPECIFIC INTERACTION BETWEEN MOLECULES ON SOLID PHASE SUPPORT | Reverse Proteomics Research Institute Co., Ltd (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-5674531-A | CONTROLLED DRUG DELIVERY, BIODEGRADATION, NONAGGREGATING | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-10-07 | — | — | US | disclosed |
| EP-0501645-B1 | Smoking composition containing a tartrate salt flavorant-release additive | PHILIP MORRIS PROD (US) | 1997-01-15 | — | — | EP | disclosed |
| US-5264605-A | Myoinsitol derivatives, process for preparing same, phosphorylating agent, and its utilization | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1993-11-23 | — | — | US | disclosed |
| EP-0305289-B1 | ENANTIOSELECTIVE PROCESS FOR PREPARING DERIVATIVES OF TRANS- OR CIS-HEMICARONALDEHYDE, AND INTERMEDIATES OBTAINED | ROUSSEL-UCLAF (FR) | 1991-10-16 | — | — | EP | disclosed |
| EP-0431197-A1 | MYOINOSITOL DERIVATIVE AND METHOD OF PRODUCTION THEREOF, AND PHOSPHORYLATING AGENT AND ITS USE | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-06-12 | — | — | EP | disclosed |
| US-4942227-A | ANTITUMOR AGENTS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1990-07-17 | — | — | US | disclosed |
| US-4487715-A | ACTIVATION, ESTERIFICATION, IMMOBILIZATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1984-12-11 | — | — | US | disclosed |
| US-4352792-A | 3-Alkoxyflavone antiviral agents | HOFFMANN-LA ROCHE INC. (US) | 1982-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060177943-A1 | Method of inhibiting nonspecific interaction between molecules on solid phase support | CD2BP2, CD14, SPR | SUCNR1 555/4885MAPK1 4086/4885NPSR1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.